<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050127</url>
  </required_header>
  <id_info>
    <org_study_id>M11-731</org_study_id>
    <nct_id>NCT01050127</nct_id>
  </id_info>
  <brief_title>A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety, tolerability, pharmacodynamics and
      pharmacokinetics of multiple doses of ABT-436 in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Assessments (i.e., electrocardiogram(ECG), clinical laboratory tests, vital signs, weight, adverse events (AE) assessment, pulmonary function tests, physical and brief neurological examinations)</measure>
    <time_frame>Days -2 through Day 7 or 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Pharmacokinetics (i.e., ABT-436 and possible metabolite levels)</measure>
    <time_frame>Day -1 through Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (i.e., biomarkers of drug effect)</measure>
    <time_frame>Day -1 through Day 7</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Low dose ABT-436</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-436 or placebo administered once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose ABT-436</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-436 or placebo administered once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose ABT-436</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-436 or placebo administered once daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-436</intervention_name>
    <description>See Arm Description for details.</description>
    <arm_group_label>Low dose ABT-436</arm_group_label>
    <arm_group_label>Mid Dose ABT-436</arm_group_label>
    <arm_group_label>High Dose ABT-436</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See Arm Description for details.</description>
    <arm_group_label>Low dose ABT-436</arm_group_label>
    <arm_group_label>Mid Dose ABT-436</arm_group_label>
    <arm_group_label>High Dose ABT-436</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age is between 18 and 55 years, inclusive.

          2. If female, subject must be postmenopausal for at least two years or surgically
             sterile.

          3. Females must have negative results for pregnancy tests prior to study drug
             administration.

          4. If male, subject must be surgically sterile or agree to be sexually inactive or agree
             to use a barrier method of birth control.

          5. Body Mass Index is 18.0 to 29.9 kg/m2 (2 = superscript number), inclusive.

          6. A condition of general good health based upon the results of a medical history,
             physical examination, vital signs, laboratory profile, and a 12-lead
             electrocardiogram.

          7. Must voluntarily sign and date an informed consent, approved by an Independent Ethics
             Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any
             screening or study-specific procedures.

        Exclusion Criteria:

          1. History of significant sensitivity or allergy to any drug.

          2. Use of known inhibitors or inducers of CYP3A within 30 days prior to the first dose of
             study drug and through the end of the study.

          3. Requirement for, or use of within the 2-week period prior to study drug
             administration, any over-the-counter or prescription medication, vitamins, minerals or
             herbal supplements on a regular basis.

          4. Receipt of any depot drug by injection within 30 days prior to study drug
             administration.

          5. Positive screen for drugs of abuse or alcohol, or recent (6-month) history of drug or
             alcohol abuse.

          6. Use of tobacco or other nicotine-containing products within the six-month period
             preceding study drug administration.

          7. Donation or loss of 550 mL of blood or more (including plasmapheresis) or receipt of a
             transfusion of any blood product within 8 weeks prior to the first dose of study drug.

          8. Receipt of an investigational product within a time period equal to 10 half-lives, if
             known, or a minimum of 6 weeks prior to study drug administration.

          9. Has a clinically significant abnormal diastolic blood pressure (&lt; 45 or &gt; 90 mm Hg),
             systolic blood pressure (&lt; 85 or &gt; 140 mm Hg) or heart rate (&lt; 45 or &gt; 100 bpm).

         10. HbA1c &gt; 6.0%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 24849</name>
      <address>
        <city>Waukegan</city>
        <state>Illinois</state>
        <zip>60085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Katherine Tracy, MD, PhD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Drug Safety</keyword>
  <keyword>Phase 1 Clinical Trial</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

